Alderley Park
Alderley Edge Cheshire
Macclesfield SK10 4TG
United Kingdom
https://www.bivictrix.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 17
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Tiffany Jane Thorn BSc. MSc., M.Sc. | CEO & Executive Director | 223,48k | N/D | 1987 |
Dr. Adrian Howd Ph.D. | Chief Business Officer & CFO | N/D | N/D | 1971 |
Simon Wallwork | Secretary | N/D | N/D | N/D |
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
L'ISS Governance QualityScore di BiVictriX Therapeutics Plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.